Torrent Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on July 28, 2025. - Financial Results
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharma's Board approved Q1 FY26 results on July 28, 2025. Consolidated revenue rose 11% YoY to Rs. 3,178 crores, with operating EBITDA up 14% at Rs. 1,032 crores (margin ~32.5%). Net profit grew 20% YoY to Rs. 548 crores, and EPS stood at Rs. 16.19 (standalone EPS Rs. 16.28). India revenue grew 11% to Rs. 1,811 crores, US was up 19% to Rs. 308 crores, Brazil rose 11%, and Germany grew 9%. The auditor (BSR & Co. LLP) issued an unqualified opinion with no qualifications. The Board also approved issuance of unsecured/secured redeemable NCDs/bonds via private placement. The filing disclosed a major acquisition: a definitive agreement to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals for ~Rs. 11,917 crores (46.39% stake at Rs. 1,600/share), plus a mandatory open offer and a proposed merger.
Strong Q1 with 20% PAT growth reflects healthy operating momentum, likely positive for the stock. However, the ~Rs. 11,917 crore JB Pharma acquisition is a significant capital outlay that will raise leverage and execution risk; investors should monitor deal approvals, financing, and post-merger integration.